EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AP39, a novel mitochondria-targeted hydrogen sulfide donor ameliorates doxorubicin-induced cardiotoxicity by regulating the AMPK/UCP2 pathway

Bin Zhang, Yangxue Li, Ning Liu, Bin Liu iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0300261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Bin Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Second Hospital of Jilin University, Nanguan District, Changchun City, Jilin Province, China. Hauptthemen laut MEDLINE: Hydrogen Sulfide. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Province Development and Reform Commission, Department of Science and Technology of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (DOX) is a broad-spectrum, highly effective antitumor agent; however, its cardiotoxicity has greatly limited its use. Hydrogen sulfide (H 2 S) is an endogenous gaseous transmitter that exerts cardioprotective effects via the regulation of oxidative stress and apoptosis and maintenance of mitochondrial function, among other mechanisms. AP39 is a novel mitochondria-targeted H 2 S donor that, at appropriate concentrations, attenuates intracellular oxidative stress damage, maintains mitochondrial function, and ameliorates cardiomyocyte injury. In this study, DOX-induced cardiotoxicity models were established using H9c2 cells and Sprague–Dawley rats to evaluate the protective effect of AP39 and its mechanisms of action. Both in vivo and in vitro experiments showed that DOX induces oxidative stress injury, apoptosis, and mitochondrial damage in cardiomyocytes and decreases the expression of p-AMPK/AMPK and UCP2. All DOX-induced changes were attenuated by AP39 treatment. Furthermore, the protective effect of AP39 was significantly attenuated by the inhibition of AMPK and UCP2. The results suggest that AP39 ameliorates DOX-induced cardiotoxicity by regulating the expression of AMPK/UCP2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydrogen SulfideRatsAnimalsCardiotoxicityAMP-Activated Protein KinasesRats, Sprague-DawleyCell LineDoxorubicinMyocytes, CardiacOxidative StressMitochondriaApoptosis

Substanzen

Hydrogen SulfideAMP-Activated Protein KinasesDoxorubicin

Autor:innen und Institutionen

  • The Second Hospital of Jilin University, Nanguan District, Changchun City, Jilin Province, China.

ORCID-Profile: Bin Liu

Förderung

  • Jilin Province Development and Reform Commission
  • Department of Science and Technology of Jilin Province

Zitieren

APA

Zhang, B., Li, Y., Liu, N., & Liu, B. (2024). AP39, a novel mitochondria-targeted hydrogen sulfide donor ameliorates doxorubicin-induced cardiotoxicity by regulating the AMPK/UCP2 pathway. PLOS ONE. https://doi.org/10.1371/journal.pone.0300261

Vancouver

Zhang B, Li Y, Liu N, Liu B. AP39, a novel mitochondria-targeted hydrogen sulfide donor ameliorates doxorubicin-induced cardiotoxicity by regulating the AMPK/UCP2 pathway. PLOS ONE. 2024. doi:10.1371/journal.pone.0300261

BibTeX
@article{Zhang2024,
  author = {Zhang, Bin and Li, Yangxue and Liu, Ning and Liu, Bin},
  title = {AP39, a novel mitochondria-targeted hydrogen sulfide donor ameliorates doxorubicin-induced cardiotoxicity by regulating the AMPK/UCP2 pathway},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0300261}
}
Kostenlos starten →